A Phase 2/3 interventional study of E3810 and E3810 in Refractory Reflux Esophagitis, sponsored by Eisai Co., Ltd.. Completed at 54 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-04-18.
Sponsored by Eisai Co., Ltd. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Esophagitis, Peptic with a site in Japan — none open to participants now, none under way, none of them phase 3. Esophagitis, Peptic · Japan.
Among the 16 studies in Esophagitis, Peptic with a site in Japan, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2008, is the only one in phase 2/3, and was the 4th registered.
83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.
Browse Esophagitis, Peptic studies →None of the 16 studies in Esophagitis, Peptic with a site in Japan is open now. The open studies under Esophagitis, Peptic, anywhere →
Of the 8 Esophagitis, Peptic studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 7 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 337 is above the median of 135 across 60 interventional studies indexed under Esophagitis, Peptic.
Median enrollment 331 across the 10 interventional studies, 1,876 across the 6 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 5 most frequent:
Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Eisai Co., Ltd. has 2 studies filed under Esophagitis, Peptic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Esophagitis, Peptic with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of E3810 tablets in patients with Proton Pump Inhibitor-resistant reflux esophagitis.
This is a multicenter, randomized, double-blinded study. The efficacy with E3810 20 mg once daily is compared with E3810 20 mg twice daily and 10 mg twice daily using endoscopic recovery. The frequency of adverse event, etc., will be compared among 3 groups for safety assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: E3810
Drug: E3810
Drug: E3810
Drug pages: Rabeprazole · E-3810
20 mg taken orally, once a day for 8 weeks.
Also known as: Aciphex
Drug pages: Rabeprazole · E-3810
10 mg, taken orally, twice a day for 8 weeks.
Also known as: Aciphex
Drug pages: Rabeprazole · E-3810
20 mg taken orally, twice a day for 8 weeks.
Also known as: Aciphex
Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N)
Grade N indicates a normal appearance of lower esophageal mucosa
Time frame: 8 weeks
This study was recruited at 71 centers in Japan during the period of 17-Oct-2008 to 12-Nov-2009.
| Milestone | E3810 20 mg Once Daily | E3810 10 mg Twice Daily | E3810 20 mg Twice Daily |
|---|---|---|---|
| Started | 113 | 111 | 113 |
| Completed | 102 | 103 | 100 |
| Not completed | 11 | 8 | 13 |
| Withdrew: Adverse event | 1 | 3 | 6 |
| Withdrew: Refusal to continue participation | 6 | 4 | 5 |
| Withdrew: Physician decision | 0 | 1 | 1 |
| Withdrew: Protocol violation | 3 | 0 | 1 |
| Withdrew: Incorrect drug was allocated | 1 | 0 | 0 |
Grade N indicates a normal appearance of lower esophageal mucosa
| Percentage of Participants | E3810 20 mg Once Daily | E3810 10 mg Twice Daily | E3810 20 mg |
|---|---|---|---|
| Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N) | 58.8 | 78.4 | 77.0 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| E3810 20 mg Once Daily | — | 3/112 (2.7%) | 27/112 (24.1%) |
| E3810 10 mg Twice Daily | — | 6/111 (5.4%) | 25/111 (22.5%) |
| E3810 20 mg | — | 5/114 (4.4%) | 20/114 (17.5%) |
| Event | E3810 20 mg Once Daily | E3810 10 mg Twice Daily | E3810 20 mg |
|---|---|---|---|
| GastroenteritisInfections and infestations | 0/112 | 1/111 | 1/114 |
| Putamen haemorrhageNervous system disorders | 0/112 | 1/111 | 0/114 |
| Cardiac failureCardiac disorders | 0/112 | 1/111 | 0/114 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/112 | 1/111 | 0/114 |
| DermatitisSkin and subcutaneous tissue disorders | 0/112 | 1/111 | 0/114 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/112 | 1/111 | 0/114 |
| Intracranial aneurysmNervous system disorders | 1/112 | 0/111 | 0/114 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/112 | 0/111 | 0/114 |
| Back painMusculoskeletal and connective tissue disorders | 1/112 | 0/111 | 0/114 |
| CellulitisInfections and infestations | 0/112 | 0/111 | 1/114 |
| Event | E3810 20 mg Once Daily | E3810 10 mg Twice Daily | E3810 20 mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/112 | 7/111 | 4/114 |
| Blood thyroid stimulating hormone increasedInvestigations | 3/112 | 7/111 | 7/114 |
| DiarrhoeaGastrointestinal disorders | 2/112 | 5/111 | 1/114 |
| Blood triglycerides increasedInvestigations | 5/112 | 1/111 | 1/114 |
| ConstipationGastrointestinal disorders | 2/112 | 3/111 | 5/114 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 4/112 | 2/111 | 2/114 |
| Alanine aminotransferase increasedInvestigations | 3/112 | 0/111 | 0/114 |
| Age Continuous(years) | E3810 20 mg Once Daily | E3810 10 mg Twice Daily | E3810 20 mg Twice Daily | Total |
|---|---|---|---|---|
| Mean | 64.5 ± 13.9 | 65.5 ± 13.3 | 66.6 ± 13.8 | 65.5 ± 13.6 |
| Sex: Female, Male(Participants) | E3810 20 mg Once Daily | E3810 10 mg Twice Daily | E3810 20 mg Twice Daily | Total |
|---|---|---|---|---|
| Female | 53 | 59 | 62 | 174 |
| Male | 57 | 52 | 49 | 158 |
| Race/Ethnicity, Customized(participants) | E3810 20 mg Once Daily | E3810 10 mg Twice Daily | E3810 20 mg Twice Daily | Total |
|---|---|---|---|---|
| Asian | 110 | 111 | 111 | 332 |
The record gives a start of Oct 2008, a primary completion of Nov 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rabeprazole · E-3810